One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their ...
Vertex has secured a label expansion through the FDA's Commis | Vertex Pharmaceuticals has gained a label expansion from the ...
In a study published in Science Translational Medicine, a team of researchers led by Dr. Wang Yu from the Shenzhen Institutes ...
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
In late June 2026, CRISPR Therapeutics AG was added to several Russell growth indexes, including the Russell 2000 Growth, ...
FDA expands Casgevy CRISPR gene therapy to children aged 2+ with sickle cell disease and beta thalassemia, enabling earlier ...
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...
The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.
A team of researchers led by Professor Akitsu Hotta (Department of Clinical Application) developed a comprehensive framework ...
9d
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results